Ying J. Buechler

Former Director-Protein Sciences at Ambrx, Inc.

Ying J. Buechler

Ying J. Buechler

Former Director-Protein Sciences at Ambrx, Inc.

Overview
RelSci Relationships

72

Relationships
RelSci Relationships are individuals Ying J. Buechler likely has professional access to. A relationship does not necessarily indicate a personal connection.

President, Green Cross Holdings at Stemedica Cell Technologies, Inc.

Relationship likelihood: Average

Former Chief Business Officer at Ambrx, Inc.

Relationship likelihood: Average

Lead Scientist at Ambrx, Inc.

Relationship likelihood: Average

Associate Director at Ambrx, Inc.

Relationship likelihood: Average

Chief Executive Officer & Director at Fount Therapeutics LLC

Relationship likelihood: Average

Director Project Management at Ambrx, Inc.

Relationship likelihood: Average

Director at Ambrx, Inc.

Relationship likelihood: Average

Advisor, Endocrinology & Drug Development at Thomas McNerney Ptn

Relationship likelihood: Average

Group Leader at Ambrx, Inc.

Relationship likelihood: Average

Group Leader at Ambrx, Inc.

Relationship likelihood: Average

Paths to Ying J. Buechler
Potential Connections via
Relationship Science
You
Ying J. Buechler
Former Director-Protein Sciences at Ambrx, Inc.
Education
B.S Chemistry

Peking University is a comprehensive and national key university. The campus, known as "Yan Yuan"(the garden of Yan), is situated at Haidian District in the western suburb of Beijing, with a total area of 2,743,532 square metres (or 274 hectares). It stands near to the Yuanmingyuan Garden and the Summer Palace. Peking University is proud of its outstanding faculty, including 53 members of the Chinese Academy of Sciences (CAS), 7 members of the Chinese Academy of Engineering (CAE), and 14 members of the Third World Academy of Sciences (TWAS). The university has effectively combined research on important scientific subjects with the training of personnel with a high level of specialized knowledge and professional skill as demanded by the country's socialist modernization. It strives not only for improvements in teaching and research work, but also for the promotion of interaction and mutual promotion among various disciplines. Thus Peking University has become a center for teaching and research and a university of a new type, embracing diverse branches of learning such as basic and applied sciences, social sciences and the humanities, and sciences of medicine, management, and education. Its aim is to rank among the world's best universities in the future

Ph.D Biochemistry

The University of California, San Diego (also referred to as UC San Diego or UCSD) is a public research university located in La Jolla, California, United States. Established in 1960 near the pre-existing Scripps Institution of Oceanography, UCSD is the seventh oldest of the 10 University of California campuses and offers over 200 undergraduate and graduate degree programs. UCSD is one of America's Public Ivy universities, which recognizes top public research universities in the United States.

Career History
Director-Protein Sciences
2010

Ambrx, Inc. operates as a biopharmaceutical company, which engages in discovering and developing protein therapeutics. It offers non-native amino acids through expanded genetic code to both generate novel bio therapeutics. The company was founded by Richard DiMarchi, Peter G. Schultz, and Troy E. Wilson on April 15, 2003 and is headquartered in La Jolla, CA.

Director, Protein Services
2000 - Prior

aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Vice President-Development
1996 - 2003

EGEN, Inc. operates as a clinical stage biopharmaceutical company which develops novel proprietary nanoparticle delivery technology for therapeutic use. EGEN's technology platform is very broad, including polymer, cationic lipid, and molecular biology-based approaches to delivery of nucleic acid and anti-cancer drugs. The primary activities of the company are the application of the TheraPlas and TheraSilence platforms to the treatment of human disease.EGEN's lead candidate, EGEN-001, is in Phase II clinical testing for ovarian cancer and in Phase I clinical testing for colorectal cancer. In addition, EGEN is pursuing pre-clinical development of its TheraSilence RNAi delivery program for multiple disease applications, as well as other novel disruptive technologies focused on creating the next generation of synthetic nanoparticle delivery systems and nucleic acid-based therapies. It is also active in pursuing partnerships and working with external collaborators to further develop its delivery technology for multiple applications.EGEN offers cutting-edge research services relating to non-viral polymeric gene carrier systems, and other approaches for the delivery of nucleic acid and anti-cancer drugs. The company's synthetic biocompatible delivery vehicles can be used to deliver therapeutic genes, inhibitory RNA (RNAi), and small molecules by protecting the therapeutic cargo from degradation, promoting uptake by target cells, and facilitating intracellular trafficking. EGEN was founded in 2002 by Sung Wan Kim and is headquartered in Huntsville, AL.

Other Affiliations
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Ying J. Buechler. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Ying J. Buechler's profile does not indicate a business or promotional relationship of any kind between RelSci and Ying J. Buechler.